Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2009

01-06-2009 | Guidelines

Chapter 8. CKD and lifestyle-related diseases

Published in: Clinical and Experimental Nephrology | Issue 3/2009

Login to get access

Excerpt

  • An unhealthy lifestyle, such as obesity, insufficient exercise, alcohol, smoking, and other stresses, are assumed to be implicated in the development of CKD.
  • Improvement in lifestyle has proven valuable in managing/treating CKD development and progression.
  • Lifestyle-related diseases and metabolic syndrome have become popular subjects (Table 8-1). A lifestyle-related disease is defined as “a disorder whose development is greatly affected by individual lifestyle habits as well as genetic background”. Metabolic syndrome is a concept that excessive eating and lack of exercise causes fat accumulation in visceral organs, resulting in hypertension, diabetes, and dyslipidemia. Insulin resistance is considered to be an underlying causal factor in metabolic syndrome.
    Table 8-1
    Criteria of metabolic syndrome
    Storage of visceral fat (visceral adiopocytes)
       Waist circumference
    Men ≥ 85 cm
    Women ≥ 90 cm
    Area of visceral fat: men/women ≥100 cm2
    Above and following factor of 2 and over
      Hypertriglyceridemia and/or low high-density lipoprotein cholesterol
    ≥50 mg/dL and/or <40 mg/dL
      Systolic blood pressure and/or diastolic blood pressure
    ≥130 mmHg and/or ≥85 mmHg
      Fasting blood glucose
    ≥110 mg/dL
    Data were obtained, with modification, from the J Jpn Soc Int Med 2005;94:794–809 (in Japanese)
  • Lifestyle-related disease and metabolic syndrome are closely related to the development of CKD. Obesity, particularly abdominal obesity that accumulates visceral fat, can easily cause proteinuria or reduced kidney function. An epidemiologic study conducted in Japan has reported that patients with metabolic syndrome had a higher cumulative incidence and relative risk of CKD (Fig. 8-1).
  • The prevalence of metabolic syndrome is currently increasing among the Japanese general population. Kidney dysfunction due to obesity is implied by insulin resistance, the magnitude of which has a positive relationship with the degree of proteinuria. Insulin resistance increases with decreasing in kidney function, thus producing vicious cycle. A similar vicious cycle arises in CKD between risk factors, such as high blood pressure and dyslipidemia (Fig. 8-2). It has recently been acknowledged that high blood pressure or obesity without diabetes also causes kidney dysfunction.
Metadata
Title
Chapter 8. CKD and lifestyle-related diseases
Publication date
01-06-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0138-x

Other articles of this Issue 3/2009

Clinical and Experimental Nephrology 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.